Latest:
Common Questions From Patients About Adalimumab Biosimilars
Drs Lio, Botsoglou, and Alexrad discuss the most asked questions and common concerns patients have on adalimumab biosimilars.
© 2025 MJH Life Sciences™ and Center for Biosimilars®. All rights reserved.
Authors
Travis Brewer
Travis Brewer serves as the vice president of payer and public health strategy at Texas Oncology.
Latest:
Enhancing Biosimilar Adoption in Value-Based Oncology Care
Travis Brewer, vice president of payer and public health strategy at Texas Oncology, discusses the role of biosimilars in making cancer care more affordable and accessible, as well as the need for greater payer trust in oncologists’ treatment decisions.
Craig Burton
Criag Burton is the senior vice president of policy and strategic alliances at the Association for Accessible Medicines. He is also the executive director of the Biosimilars Council. In his current role, Craig is responsible for leading policy development and issues management for AAM, directing the Biosimilars Council, and building relationships with strategic partners in the health care sector, including patient advocacy groups.
Latest:
Opinion: The Inflation Reduction Act is a Step Backward for Biosimilar Competition
In response to another opinion piece, Craig Burton, from the Association for Accessible Medicines, argued that the Inflation Reduction Act of 2022 could prevent biosimilar competition, and lower drug prices as a result.
Josh Canavan, PharmD
head of pharmacy at RazorMetrics
Latest:
How AI Can Help Address Cost-Related Nonadherence to Biologic, Biosimilar Treatment
Despite saving billions, biosimilars still account for only a small share of the biologics market—what's standing in the way of broader adoption and how can artificial intelligence (AI) help change that?
James D. Chambers, PhD, MPharm, MSc
James D. Chambers, PhD, MPharm, MSc, is an associate professor at the Tufts Medical Center Institute for Clinical Research and Health Policy Studies. Chambers leads the Tufts Medical Center Specialty Drug Evidence and Coverage Database and the Medicare National Coverage Decisions Database, making him a key expert in analyzing drug policy, reimbursement trends, and health care economics. Chambers is also partnering with Organon to share his insights as a health economist around the complex landscape of biosimilars.
Latest:
The Banking of Biosimilars: Insights From a Leading Health Economist
Biosimilars have the potential to reduce health care costs and expand patient access, but economic and policy barriers affect adoption, explored James D. Chambers, PhD, MPharm, MSc, associate professor at the Tufts Medical Center Institute for Clinical Research and Health Policy Studies, in an interview.
Rebecca Clegg, JD
Rebecca Clegg is an associate in Axinn’s Intellectual Property group. Her practice focuses on complex intellectual property litigation and counseling, in the fields of medical devices, pharmaceuticals and biotechnology.
Latest:
Opinion: The Legal and Regulatory Year in Review
Intellectual property law attorneys from Axinn discuss regulatory and legal events in 2020 that will affect biosimilar markets in 2021.
Christina Corridon, MPH, MBA
Christina Corridon, MPH, MBA, is a principal in
Latest:
The Next Frontier: Oncology Biosimilars in 2025 and Beyond
The US oncology biosimilar market has rapidly evolved since its launch in 2017, driven by steep price discounts, payer adoption, and provider confidence, with an upcoming wave of biosimilars targeting blockbuster biologics promising further market growth, cost savings, and broader patient access.
Rabiah Dys, PharmD
Rabiah Dys, PharmD, is Senior Vice President of Clinical Program Development and Fellowship Program Director on Health Equity and Systems Thinking for CPS Solutions
Latest:
Contributor: Self-Administered Biosimilars Are Coming Quickly—Is Your Clinic Ready?
Four pharmacists offer advice for clinics on how to prepare for new self-administered biosimilar products, including adalimumab biosimilars, and overcome emerging administrative challenges.
Advertisement
Advertisement